相似文献
1
Immune therapies.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1217-30, x-xi. doi: 10.1016/j.hoc.2007.08.011.
2
Dendritic cells in clinical trials for multiple myeloma.
Methods Mol Med. 2005;109:127-36. doi: 10.1385/1-59259-862-5:127.
3
4
Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Cytotherapy. 2006;8(3):277-89. doi: 10.1080/14653240600735701.
5
Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15.
6
Immunotherapy in multiple myeloma: current strategies and future prospects.
Expert Rev Vaccines. 2003 Jun;2(3):391-8. doi: 10.1586/14760584.2.3.391.
7
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Br J Haematol. 2000 Mar;108(4):805-16. doi: 10.1046/j.1365-2141.2000.01958.x.
8
Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
J Immunol. 2002 Nov 1;169(9):5227-35. doi: 10.4049/jimmunol.169.9.5227.
9
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.
10
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Clin Exp Immunol. 2012 Nov;170(2):167-77. doi: 10.1111/j.1365-2249.2012.04642.x.
引用本文的文献
1
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.
Leukemia. 2016 Feb;30(2):379-89. doi: 10.1038/leu.2015.228. Epub 2015 Aug 21.
2
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.
Br J Haematol. 2013 Nov;163(3):343-51. doi: 10.1111/bjh.12544. Epub 2013 Aug 30.
3
New strategies in the treatment of multiple myeloma.
Clin Cancer Res. 2013 Jul 1;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881. Epub 2013 Mar 20.
本文引用的文献
1
Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.
J Immunol. 2017 Feb 1;198(3):981-985.
2
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.
Nat Immunol. 2007 Sep;8(9):942-9. doi: 10.1038/ni1496. Epub 2007 Aug 5.
3
Development, cytokine profile and function of human interleukin 17-producing helper T cells.
Nat Immunol. 2007 Sep;8(9):950-7. doi: 10.1038/ni1497. Epub 2007 Aug 5.
4
Host immune system gene targeting by a viral miRNA.
Science. 2007 Jul 20;317(5836):376-81. doi: 10.1126/science.1140956.
5
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.
Science. 2007 Jul 13;317(5835):256-60. doi: 10.1126/science.1145697. Epub 2007 Jun 14.
6
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.
Nat Immunol. 2007 Jun;8(6):639-46. doi: 10.1038/ni1467. Epub 2007 May 7.
7
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
J Exp Med. 2007 Apr 16;204(4):831-40. doi: 10.1084/jem.20062387. Epub 2007 Mar 26.
8
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.
Nature. 2007 Apr 5;446(7136):685-9. doi: 10.1038/nature05673. Epub 2007 Mar 21.
9
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.
Immunity. 2007 Mar;26(3):371-81. doi: 10.1016/j.immuni.2007.02.009.
10
Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.
J Immunol. 2007 Mar 1;178(5):2721-9. doi: 10.4049/jimmunol.178.5.2721.
Zotero 插件